ARTICLE | Clinical News
Iclusig ponatinib regulatory update
October 17, 2016 7:00 AM UTC
Japan approved an NDA from Otsuka for Iclusig ponatinib to treat chronic myelogenous leukemia (CML) resistant or intolerant to previous therapy and relapsed or treatment-resistant Philadelphia chromos...